Artelo biosciences reports four-month 2021 financial results in connection with its amended fiscal year end and provides business update

Reports $25.6 million in cash and marketable securities as of december 31, 2021, expected to support operations into second half of 2023 reports $25.6 million in cash and marketable securities as of december 31, 2021, expected to support operations into second half of 2023
ARTL Ratings Summary
ARTL Quant Ranking